Ganaxolone | C22H36O2 - PubChem
Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo- controlled, phase 3 trial - The Lancet Neurology
Clinical trials to date in fragile X syndrome by drug and study type | Download Table
Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials | Business Wire
tm2037816d1_8k.htm
Epilepsy Therapy Ganaxolone Inhibits Seizure-Triggering Processes, Study Shows
Intramuscular allopregnanolone and ganaxolone in a mouse model of treatment‐resistant status epilepticus - Zolkowska - 2018 - Epilepsia - Wiley Online Library
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results | Business Wire
Marinus Pharma Delays Status Epilepticus, IV Ganaxolone Clinical Trials Into 2023
First Patient Enrolled in Ganaxolone Phase 3 Refractory Status Epilepticus Trial
A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome | Journal of Neurodevelopmental Disorders | Full Text
Ganaxolone facilitates fear extinction and blocks contextual fear... | Download Scientific Diagram
Marinus Pharmaceuticals, Inc. Enrolls First Patient in Pivotal Phase 3 Clinical Trial of IV Ganaxolone in Refractory Status Epilepticus · BioBuzz
Ganaxolone
Randomized, double‐blind, placebo‐controlled phase 2 study of ganaxolone as add‐on therapy in adults with uncontrolled partial‐onset seizures - Sperling - 2017 - Epilepsia - Wiley Online Library
Dose-response (top) and time-course (bottom) data for ganaxolone,... | Download Scientific Diagram
Pipeline - Marinus Pharmaceuticals : Marinus Pharmaceuticals
Ganaxolone Effective for Rare Form of Childhood Epilepsy – Consult QD
Ganaxolone | New Drug Approvals
Marinus Announces Positive Preliminary Data for Ganaxolone - Drug Discovery and Development
Marinus starts Phase lll trial of ganaxolone for CDD - Clinical Trials Arena
Characterization of the Anticonvulsant Properties of Ganaxolone (CCD 1042; 3α-Hydroxy-3β-methyl-5α-pregnan-20-one), a Selective, High-Affinity, Steroid Modulator of the γ-Aminobutyric AcidA Receptor | Journal of Pharmacology and Experimental Therapeutics
